173 related articles for article (PubMed ID: 32684030)
1. Predicting Aggressive Behavior in Nonfunctional Pancreatic Neuroendocrine Tumors With Emphasis on Tumor Size Significance and Survival Trends: A Population-Based Analysis of 1787 Patients.
Fathi AH; Romanyshyn J; Barati M; Choudhury U; Chen A; Sosa JA
Am Surg; 2020 May; 86(5):458-466. PubMed ID: 32684030
[TBL] [Abstract][Full Text] [Related]
2. Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.
Mirkin KA; Hollenbeak CS; Wong J
J Surg Res; 2017 May; 211():206-214. PubMed ID: 28501118
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of resected nonfunctional pancreatic neuroendocrine tumors: Do size and symptoms matter?
Sallinen V; Haglund C; Seppänen H
Surgery; 2015 Dec; 158(6):1556-63. PubMed ID: 26070847
[TBL] [Abstract][Full Text] [Related]
4. Impact of extent of surgery on survival in patients with small nonfunctional pancreatic neuroendocrine tumors in the United States.
Gratian L; Pura J; Dinan M; Roman S; Reed S; Sosa JA
Ann Surg Oncol; 2014 Oct; 21(11):3515-21. PubMed ID: 24841347
[TBL] [Abstract][Full Text] [Related]
5. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Demographics, Tumor Characteristics, and Survival Between Pancreatic Adenocarcinomas and Pancreatic Neuroendocrine Tumors: A Population-based Study.
Yadav S; Sharma P; Zakalik D
Am J Clin Oncol; 2018 May; 41(5):485-491. PubMed ID: 27322698
[TBL] [Abstract][Full Text] [Related]
7. Nonfunctional pancreatic neuroendocrine tumors <2 cm on preoperative imaging are associated with a low incidence of nodal metastasis and an excellent overall survival.
Toste PA; Kadera BE; Tatishchev SF; Dawson DW; Clerkin BM; Muthusamy R; Watson R; Tomlinson JS; Hines OJ; Reber HA; Donahue TR
J Gastrointest Surg; 2013 Dec; 17(12):2105-13. PubMed ID: 24101447
[TBL] [Abstract][Full Text] [Related]
8. Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors.
Zhang IY; Zhao J; Fernandez-Del Castillo C; Braun Y; Razmdjou S; Warshaw AL; Lillemoe KD; Ferrone CR
J Gastrointest Surg; 2016 Feb; 20(2):277-83. PubMed ID: 26691146
[TBL] [Abstract][Full Text] [Related]
9. Predicting aggressive behavior in nonfunctioning pancreatic neuroendocrine tumors.
Cherenfant J; Stocker SJ; Gage MK; Du H; Thurow TA; Odeleye M; Schimpke SW; Kaul KL; Hall CR; Lamzabi I; Gattuso P; Winchester DJ; Marsh RW; Roggin KK; Bentrem DJ; Baker MS; Prinz RA; Talamonti MS
Surgery; 2013 Oct; 154(4):785-91; discussion 791-3. PubMed ID: 24074416
[TBL] [Abstract][Full Text] [Related]
10. Operative resection in early stage pancreatic neuroendocrine tumors in the United States: Are we over- or undertreating patients?
Chivukula SV; Tierney JF; Hertl M; Poirier J; Keutgen XM
Surgery; 2020 Jan; 167(1):180-186. PubMed ID: 31537303
[TBL] [Abstract][Full Text] [Related]
11. Life expectancy in pancreatic neuroendocrine cancer.
Brooks JC; Shavelle RM; Vavra-Musser KN
Clin Res Hepatol Gastroenterol; 2019 Feb; 43(1):88-97. PubMed ID: 30220478
[TBL] [Abstract][Full Text] [Related]
12. Palliative Resection of Primary Tumor in Metastatic Nonfunctioning Pancreatic Neuroendocrine Tumors.
Ye H; Xu HL; Shen Q; Zheng Q; Chen P
J Surg Res; 2019 Nov; 243():578-587. PubMed ID: 31031022
[TBL] [Abstract][Full Text] [Related]
13. Aggressive surgical resection in the management of pancreatic neuroendocrine tumors: when is it indicated?
Hodul PJ; Strosberg JR; Kvols LK
Cancer Control; 2008 Oct; 15(4):314-21. PubMed ID: 18813199
[TBL] [Abstract][Full Text] [Related]
14. Reappraisal of a 2-cm Cutoff Size for the Management of Nonfunctional Pancreatic Neuroendocrine Tumors: A Population-Based Study.
Yang Z; Zhang D; Shi G
Front Endocrinol (Lausanne); 2022; 13():928341. PubMed ID: 35923628
[TBL] [Abstract][Full Text] [Related]
15. The value of serum chromogranin A as a predictor of tumor burden, therapeutic response, and nomogram-based survival in well-moderate nonfunctional pancreatic neuroendocrine tumors with liver metastases.
Han X; Zhang C; Tang M; Xu X; Liu L; Ji Y; Pan B; Lou W
Eur J Gastroenterol Hepatol; 2015 May; 27(5):527-35. PubMed ID: 25822862
[TBL] [Abstract][Full Text] [Related]
16. Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.
Hill JS; McPhee JT; McDade TP; Zhou Z; Sullivan ME; Whalen GF; Tseng JF
Cancer; 2009 Feb; 115(4):741-51. PubMed ID: 19130464
[TBL] [Abstract][Full Text] [Related]
17. Resection versus expectant management of small incidentally discovered nonfunctional pancreatic neuroendocrine tumors.
Rosenberg AM; Friedmann P; Del Rivero J; Libutti SK; Laird AM
Surgery; 2016 Jan; 159(1):302-9. PubMed ID: 26547726
[TBL] [Abstract][Full Text] [Related]
18. Surveillance and comparison of surgical prognosis for asymptomatic and symptomatic non-functioning pancreatic neuroendocrine tumors.
Ge W; Zhou D; Xu S; Wang W; Zheng S
Int J Surg; 2017 Mar; 39():127-134. PubMed ID: 28137555
[TBL] [Abstract][Full Text] [Related]
19. Surgery Versus Surveillance for Well-Differentiated, Nonfunctional Pancreatic Neuroendocrine Tumors: An 11-Year Analysis of the National Cancer Database.
Assi HA; Mukherjee S; Kunz PL; Machiorlatti M; Vesely S; Pareek V; Hatoum H
Oncologist; 2020 Feb; 25(2):e276-e283. PubMed ID: 32043766
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.
Deng BY; Liu F; Yin SN; Chen AP; Xu L; Li B
Clin Res Hepatol Gastroenterol; 2018 Jun; 42(3):261-268. PubMed ID: 29307515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
